Ransom Advisory’s Edwards Lifesciences EW Stock Holding History

Ransom Advisory’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,000	Closed	-$78.2K	–	312
2025 Q2	$78.2K	Hold	1,000	–	–	0.04%	146
2025 Q1	$72.5K	Buy	+1,000	New	+$71.6K	0.04%	159

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return

Ransom Advisory's EW Position: Q3 2025 in Review

Ransom Advisory sold out of Edwards Lifesciences (EW) in Q3 2025, closing a stake of 1,000 shares — an estimated $78.2K sold.

Ransom Advisory first reported a position in EW in Q1 2025 and held it in 2 quarters. The position peaked at $78.2K in Q2 2025. 1,254 funds tracked by Wall St. Rank hold EW as of Q3 2025.

Ransom Advisory reported no remaining Edwards Lifesciences position as of Q3 2025 after selling out during the quarter.
Ransom Advisory sold 1,000 Edwards Lifesciences shares in Q3 2025, an estimated $78.2K.
Ransom Advisory first reported a position in Edwards Lifesciences in Q1 2025 and held it in 2 quarters.
Ransom Advisory's Edwards Lifesciences position peaked at $78.2K in Q2 2025.
1,254 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2025.

Based on Ransom Advisory's 13F filing for Q3 2025, filed 3 Oct 2025.